X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
EQ001 (itolizumab) is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells. It is being evaluated for the treatment of Lupus Nephritis.
Lead Product(s): Itolizumab
Therapeutic Area: Nephrology Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
EQ001 (itolizumab) is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
EQ001 (Itolizumab), is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which can drive several immuno-inflammatory diseases. This unique molecule holds the potential for multiple high-value indications.
Lead Product(s): Itolizumab
Therapeutic Area: Gastroenterology Product Name: EQ001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $164.5 million Upfront Cash: $26.0 million
Deal Type: Agreement December 06, 2022
Details:
EQ001 (itolizumab), a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Lead Product(s): Itolizumab,EQ101
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
EQ001 (itolizumab) is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Nephrology Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
EQ001 (Itolizumab) is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating both the activity and trafficking of the pathogenic T cells driving a number of immuno-inflammatory diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
The translational work presented specifically characterizes CD6 expression levels and demonstrates the suppressive effect of EQ001 (itolizumab) on the activity of CD4 and CD8 T cells from transplant patients with aGVHD.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Data demonstrated that across all dose cohorts Day 29 complete response (CR) rate was 52%, overall response rate (ORR) was 64% and that the highest Day 29 CR rate of 61% was achieved in subjects treated with itolizumab within 72 hours of starting systemic corticosteroids.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
The Phase 3 EQUATOR study for EQ001(Itolizumab) is supported by results generated in the EQUATE study of 25 high-risk aGVHD patients, where CR and ORR at Day 29 were 52% and 64% respectively, across all doses.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2022
Details:
ALZUMAb-L (Itolizumab), an anti-CD6 monoclonal antibody targets CD6-ALCAM pathway, commercialized in India since 2013 for plaque psoriasis, and emergency use authorization in COVID-19. Equillium has expanded its EQUALISE study in Systemic Lupus Erythematosus in India.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab-L
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Equillium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2021
Details:
Itolizumab was well tolerated with most adverse events characterized as mild to moderate in severity, consisting primarily of injection site reactions and transient lymphopenia events consistent with prior experience of itolizumab administration.
Lead Product(s): Itolizumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2021
Details:
The EQUALISE study is a Phase 1b open-label proof-of-concept multiple ascending-dose clinical study of itolizumab in patients with systemic lupus erythematosus and lupus nephritis.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
Details:
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
The research collaboration will study how CD6 monoclonal antibodies, such as itolizumab, modulate T cell responses and explore the role of the CD6-ALCAM pathway in rheumatic diseases.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 07, 2021
Details:
The study, described in the late-breaking oral presentation titled “Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
The Company intends to use the net proceeds primarily to fund the continued development of the itolizumab pipeline, potential acquisitions and development of new products, and for working capital and general corporate purposes.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Decheng Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 05, 2021
Details:
The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids, as no other therapeutics are currently approved for this indication.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
Data will be presented demonstrating that modulation of the CD6-ALCAM pathway with itolizumab improves kidney and skin pathology in mouse models of SLE.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. Patients enrolled in EQUINOX trial will be randomized 1:1 to receive either itolizumab or placebo in addition to best supportive care for the treatment for Covid-19.
Lead Product(s): Itolizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocontrolled
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
These findings suggest the CD6-ALCAM pathway may contribute in multiple ways to asthma pathology. These data support Equillium’s ongoing clinical development of itolizumab for the treatment of patients with moderateto-severe uncontrolled asthma.
Lead Product(s): Itolizumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EQ001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
The FDA provided positive feedback supporting Equillium’s clinical development plans for evaluating itolizumab (EQ001) as a potential treatment for hospitalized patients with COVID-19.
Lead Product(s): Itolizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: EQ001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
Across the first two dose cohorts itolizumab has been generally well tolerated to date, and five of seven patients achieved a complete response (CR) by Day 29.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Alzumab
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with moderate to severe ARDS.
Lead Product(s): Itolizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Alzumab
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.
Lead Product(s): Itolizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Alzumab
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2020
Details:
The research, conducted in mouse models, demonstrates that blockade of the CD6-ALCAM pathway with anti-CD6 antibodies reduces incidence and severity of both GVHD and gastro-intestinal inflammation.
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
